Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Contributed by: PR Newswire

Tags

CALLIDITAS-Trial

More Like This

Calliditas initiates clinical study to evaluate setanaxib in Alport Syndrome

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome

Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

Calliditas provides setanaxib patent update

Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023